Rothwell Figg

Blog Authors

Latest from Rothwell Figg

On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options to license Voyager’s adeno-associated virus (AAV) capsids for gene therapies.

Voyager is a Massachusetts-based company developing AAV-based gene therapies.  The
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million

Last month, in the case In re: MaxPower Semiconductor, Inc., the Court of Appeals for the Federal Circuit (“the CAFC”) dismissed an appeal by MaxPower Semiconductor, Inc. (“MaxPower”) of four determinations to institute inter partes review (“IPR”) of four of
Continue Reading Judge O’Malley Dissents from the Majority on the Enforceability of Arbitration Agreements in IPR Proceedings

The U.K. released a National AI Strategy with a ten-year plan to make Britain a global AI superpower in our new age of artificial intelligence.  The Strategy intends to “signal to the world [the U.K.’s] intention to build the most
Continue Reading The U.K. National AI Strategy Begins with Consultations on Copyright, Patent, and Data Protection Regime

On September 16, 2021, eleven congressional leaders (“the Signors”) sent a letter to Andrew Hirshfeld, the acting director of the United States Patent and Trademark Office (“USPTO”), requesting the USPTO to reevaluate the Patent Trial and Appeal Board’s (“PTAB”) view
Continue Reading Key Members of Congress Urge USPTO to Curtail Discretionary Denials of IPR Petitions to Help Lower Drug Costs by Breaking Patent Thickets

On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop and commercialize a potential gene therapy drug developed by Regenxbio for treating age-related macular degeneration (wet AMD), diabetic retinopathy, and
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy